NanoFlu pivotal Phase 3 clinical trial initiated October 2019 with top-line data expected in the first quarter of 2020 Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company...More>>

GAITHERSBURG, Md. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2019 financial and operating results following the close of...More>>

First participants enrolled in pivotal Phase 3 clinical trial of NanoFlu   Top-line clinical data expected in the first quarter of 2020   Phase 3 results expected to support a future BLA and licensure of NanoFlu using the FDA’s accelerated approval pathway GAITHERSBURG, Md. , Oct....More>>

GAITHERSBURG, Md. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck , President and Chief Executive Officer, will present at the Ladenburg...More>>

GAITHERSBURG, Md. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Stanley C. Erck , President and Chief Executive Officer, will present at the H. C....More>>

Data demonstrate significant vaccine efficacy against infant pneumonia through the first year of life GAITHERSBURG, Md., August 12, 2019 – Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the...More>>

GAITHERSBURG, Md. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Louis F. Fries III , M.D., Senior Vice President, Chief Medical Officer, will participate...More>>

Agreement with the FDA on Phase 3 non-inferiority immunogenicity study design for NanoFlu™ NanoFlu pivotal Phase 3 clinical trial expected to initiate in the third quarter of 2019 with top-line data in the first quarter of 2020 Strategic partnership completed with Catalent ; raised $18 million...More>>

Clinical trial expected to initiate in the fall of 2019 GAITHERSBURG, Md. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it received input from the U.S....More>>

Gaithersburg, Md. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2019 financial and operating results following the close of...More>>

GAITHERSBURG, Md., July 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and manufacturing...More>>

Pivotal Phase 3 clinical trial expected to initiate in the fall of 2019 Top-line clinical data expected in the first quarter of 2020 GAITHERSBURG, Md. , June 27, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious...More>>

Manufacturing equipment and related assets to be sold to Catalent’s Paragon Gene Therapy for $18 million in cash Over 100 manufacturing and quality employees to join Catalent Paragon Gene Therapy to take over two clinical development and manufacturing sites in Gaithersburg, MD Long-term agreement...More>>

GAITHERSBURG, Md. , June 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates on the pursuit of global licensure for ResVax™ following the Prepare™ Phase 3 clinical...More>>

GAITHERSBURG, Md. , June 04, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino , Senior Vice President, Chief Business Officer and Chief Financial Officer, will join other vaccine industry leaders for a panel discussion at the 2019 BIO International...More>>

GAITHERSBURG, Md. , May 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes due 2023 (Notes), pursuant to that certain Indenture between Novavax and The Bank of New York Mellon Trust...More>>

GAITHERSBURG, Md. , May 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders of Novavax approved an amendment to Novavax’ Second Amended and Restated Certificate of...More>>

             Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md. , May 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. , (Nasdaq: NVAX) today announced its financial results and operational highlights for the first quarter ended March 31, 2019 ....More>>

GAITHERSBURG, Md. , May 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and Microbiology at Baylor College of Medicine and Medical Director, Transplant Infectious Diseases, Texas...More>>

GAITHERSBURG, Md. , April 25, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, May 2, 2019 . Conference call details are as follows:       Date:  ...More>>

GAITHERSBURG, Md. , April 09, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Gregory M. Glenn , M.D., President of Research and Development, will share data from its global Phase 3 clinical trial of ResVax™, the respiratory syncytial virus (RSV) fusion (F) protein...More>>

Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md. , March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018 ....More>>

GAITHERSBURG, Md. , March 11, 2019 (GLOBE NEWSWIRE) --Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and year-end 2018 financial and operating results following the close of U.S. financial markets on Monday, March 18, 2019....More>>

Trial did not meet primary objective of prevention of medically significant RSV LRTI Trial did show efficacy against secondary objective (RSV LRTI hospitalization); first RSV vaccine to show Phase 3 efficacy Other pre-specified exploratory endpoints and post-hoc analyses highlight potential to...More>>

Sets the Stage for Phase 3 Clinical Trial in 2019 Phase 2 clinical trial confirmed Phase 1/2 results, again demonstrating improved immune responses over Fluzone ® High-Dose End-of-Phase 2 meeting with the FDA expected in the first half of 2019 Pivotal Phase 3 clinical trial expected to initiate in...More>>

GAITHERSBURG, Md. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference . Presentation details are as follows: Date and time: Wednesday, January 9 , 3:00 p.m. – 3:25 p.m. P.T....More>>